GlaxoSmithKlineE (BIOC) Stock Overview
Engages in production of pharmaceutical chemicals. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
BIOC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GlaxoSmithKline S.A.E Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م70.60 |
| 52 Week High | ج.م81.50 |
| 52 Week Low | ج.م34.34 |
| Beta | 0.81 |
| 1 Month Change | 5.78% |
| 3 Month Change | 10.24% |
| 1 Year Change | 74.80% |
| 3 Year Change | 110.62% |
| 5 Year Change | 150.18% |
| Change since IPO | 657.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOC | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -9.5% | -5.7% | -2.9% |
| 1Y | 74.8% | 112.2% | 53.2% |
Return vs Industry: BIOC underperformed the EG Pharmaceuticals industry which returned 116.8% over the past year.
Return vs Market: BIOC exceeded the EG Market which returned 56.4% over the past year.
Price Volatility
| BIOC volatility | |
|---|---|
| BIOC Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in EG Market | 8.5% |
| 10% least volatile stocks in EG Market | 3.4% |
Stable Share Price: BIOC has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: BIOC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Heba El Morshedy | www.gsk.com/en-gb/contact-us/worldwide/egypt |
GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in New Cairo, Egypt.
GlaxoSmithKline S.A.E Fundamentals Summary
| BIOC fundamental statistics | |
|---|---|
| Market cap | ج.م5.90b |
| Earnings (TTM) | ج.م213.23m |
| Revenue (TTM) | ج.م3.73b |
Is BIOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOC income statement (TTM) | |
|---|---|
| Revenue | ج.م3.73b |
| Cost of Revenue | ج.م3.05b |
| Gross Profit | ج.م679.77m |
| Other Expenses | ج.م466.54m |
| Earnings | ج.م213.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.55 |
| Gross Margin | 18.22% |
| Net Profit Margin | 5.72% |
| Debt/Equity Ratio | 0% |
How did BIOC perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 20:40 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GlaxoSmithKline S.A.E is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.